Yes, PD-L1 can be targeted for cancer treatment through the use of immune checkpoint inhibitors. Drugs such as Pembrolizumab and Nivolumab are monoclonal antibodies designed to block the interaction between PD-1 and PD-L1. By inhibiting this pathway, these drugs can restore the immune system's ability to recognize and attack cancer cells.
